Lv1
50 积分 2023-10-23 加入
The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025
20小时前
已完结
[Interpretation of "multiple-molecular classifier" in endometrial carcinoma]
2个月前
已完结
[Interpretation of "multiple-molecular classifier" in endometrial carcinoma]
2个月前
已关闭
皖公网安备34019202002308
